Tags

Type your tag names separated by a space and hit enter

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
Liver Int 2015; 35(12):2537-46LI

Abstract

BACKGROUND & AIMS

The I148M variant because of the substitution of C to G in PNPLA3 (rs738409) is associated with the increased risk of nonalcoholic fatty liver disease (NAFLD). In liver, I148M variant reduces hydrolytic function of PNPLA3, which results in hepatic steatosis; however, its association with the other clinical phenotype such as adiposity and metabolic diseases is not well established.

METHODS

To identify the impact of I148M variant on clinical risk factors of NAFLD, we recruited 1363 generally healthy Korean males after excluding alcoholic and secondary causes of hepatic steatosis. Central adiposity was assessed by computed tomography, and hepatic steatosis was evaluated by abdominal ultrasonography.

RESULTS

The participants were predominantly middle-aged (49.0 ± 7.1 years; range 30-60 years), and the frequency of NAFLD was 44.2%. The rs738409-G allele carriers had a 1.19-fold increased risk for NAFLD (minor allele frequency 0.43; allelic odds ratio 1.38; P = 4.3 × 10(-5)). Interestingly, the rs738409 GG carriers showed significantly lower levels of visceral and subcutaneous adiposity (P < 0.001 and = 0.015, respectively), BMI (P < 0.001), triglycerides (P < 0.001) and insulin resistance (P = 0.002) compared to CC carriers. These negative associations between clinical risk factors and rs738409-G dosage were more prominent in non-NAFLD group compared to those in NAFLD group.

CONCLUSIONS

The I148M variant, although increasing the risk of NAFLD, was associated with reduced levels of central adiposity, BMI, serum triglycerides and insulin resistance, suggesting differential roles in fat storage and distribution according to cell types and metabolic status.

Authors+Show Affiliations

Informatics Program, Boston Children's Hospital, Boston, MA, USA. Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea.Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea.Department of Family Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, South Korea.Center for Biomedical Informatics, Harvard Medical School, Boston, MA, USA.Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea.Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea.School of Computer Science and Engineering, Soongsil University, Seoul, South Korea.Samsung Genome Institute, Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, South Korea.Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, South Korea. Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, South Korea.Informatics Program, Boston Children's Hospital, Boston, MA, USA. Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

26148225

Citation

Park, Jin-Ho, et al. "I148M Variant in PNPLA3 Reduces Central Adiposity and Metabolic Disease Risks While Increasing Nonalcoholic Fatty Liver Disease." Liver International : Official Journal of the International Association for the Study of the Liver, vol. 35, no. 12, 2015, pp. 2537-46.
Park JH, Cho B, Kwon H, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015;35(12):2537-46.
Park, J. H., Cho, B., Kwon, H., Prilutsky, D., Yun, J. M., Choi, H. C., ... Kong, S. W. (2015). I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver International : Official Journal of the International Association for the Study of the Liver, 35(12), pp. 2537-46. doi:10.1111/liv.12909.
Park JH, et al. I148M Variant in PNPLA3 Reduces Central Adiposity and Metabolic Disease Risks While Increasing Nonalcoholic Fatty Liver Disease. Liver Int. 2015;35(12):2537-46. PubMed PMID: 26148225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. AU - Park,Jin-Ho, AU - Cho,BeLong, AU - Kwon,Hyuktae, AU - Prilutsky,Daria, AU - Yun,Jae Moon, AU - Choi,Ho Chun, AU - Hwang,Kyu-Baek, AU - Lee,In-Hee, AU - Kim,Jong-Il, AU - Kong,Sek Won, Y1 - 2015/07/23/ PY - 2015/04/19/received PY - 2015/06/29/accepted PY - 2015/7/7/entrez PY - 2015/7/7/pubmed PY - 2016/10/16/medline KW - I148M variant KW - insulin resistance KW - nonalcoholic fatty liver disease KW - obesity KW - triglyceride SP - 2537 EP - 46 JF - Liver international : official journal of the International Association for the Study of the Liver JO - Liver Int. VL - 35 IS - 12 N2 - BACKGROUND & AIMS: The I148M variant because of the substitution of C to G in PNPLA3 (rs738409) is associated with the increased risk of nonalcoholic fatty liver disease (NAFLD). In liver, I148M variant reduces hydrolytic function of PNPLA3, which results in hepatic steatosis; however, its association with the other clinical phenotype such as adiposity and metabolic diseases is not well established. METHODS: To identify the impact of I148M variant on clinical risk factors of NAFLD, we recruited 1363 generally healthy Korean males after excluding alcoholic and secondary causes of hepatic steatosis. Central adiposity was assessed by computed tomography, and hepatic steatosis was evaluated by abdominal ultrasonography. RESULTS: The participants were predominantly middle-aged (49.0 ± 7.1 years; range 30-60 years), and the frequency of NAFLD was 44.2%. The rs738409-G allele carriers had a 1.19-fold increased risk for NAFLD (minor allele frequency 0.43; allelic odds ratio 1.38; P = 4.3 × 10(-5)). Interestingly, the rs738409 GG carriers showed significantly lower levels of visceral and subcutaneous adiposity (P < 0.001 and = 0.015, respectively), BMI (P < 0.001), triglycerides (P < 0.001) and insulin resistance (P = 0.002) compared to CC carriers. These negative associations between clinical risk factors and rs738409-G dosage were more prominent in non-NAFLD group compared to those in NAFLD group. CONCLUSIONS: The I148M variant, although increasing the risk of NAFLD, was associated with reduced levels of central adiposity, BMI, serum triglycerides and insulin resistance, suggesting differential roles in fat storage and distribution according to cell types and metabolic status. SN - 1478-3231 UR - https://www.unboundmedicine.com/medline/citation/26148225/I148M_variant_in_PNPLA3_reduces_central_adiposity_and_metabolic_disease_risks_while_increasing_nonalcoholic_fatty_liver_disease_ L2 - https://doi.org/10.1111/liv.12909 DB - PRIME DP - Unbound Medicine ER -